Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus).

Authors

Andrea Necchi

Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy

Andrea Necchi , Yousef Zakharia , Nadeem Ghali , Michael Smith , J. E. Hamer-Maansson , Anouk Lindley , Yohann Loriot , Joshua J Meeks

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.

First Author: Enrique Grande

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).

First Author: Andrea Necchi

insert_chart_outlined

Poster

2018 Genitourinary Cancers Symposium

bookmark_border

PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).

First Author: Andrea Necchi

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer (RAD VACCINE MIBC).

First Author: Raj Satkunasivam